Chronic Heart Failure - Pipeline Review, H1 2016

Published: Apr, 2016 | Pages: 157 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Chronic Heart Failure - Pipeline Review, H1 2016

Summary

Global Markets Direct's, 'Chronic Heart Failure - Pipeline Review, H1 2016', provides an overview of the Chronic Heart Failure pipeline landscape. 

The report provides comprehensive information on the therapeutics under development for Chronic Heart Failure, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Chronic Heart Failure and features dormant and discontinued projects. 

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Chronic Heart Failure
- The report reviews pipeline therapeutics for Chronic Heart Failure by companies and universities/research institutes based on information derived from company and industry-specific sources 
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages 
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved Chronic Heart Failure therapeutics and enlists all their major and minor projects
- The report assesses Chronic Heart Failure therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type 
- The report summarizes all the dormant and discontinued pipeline projects 
- The report reviews latest news related to pipeline therapeutics for Chronic Heart Failure

Reasons To Buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage 
- Identify and understand important and diverse types of therapeutics under development for Chronic Heart Failure
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies 
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Chronic Heart Failure pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope 
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents

Table of Content 2
List of Tables 6
List of Figures 7
Introduction 8
Global Markets Direct Report Coverage 8
Chronic Heart Failure Overview 9
Therapeutics Development 10
Pipeline Products for Chronic Heart Failure - Overview 10
Pipeline Products for Chronic Heart Failure - Comparative Analysis 11
Chronic Heart Failure - Therapeutics under Development by Companies 12
Chronic Heart Failure - Therapeutics under Investigation by Universities/Institutes 13
Chronic Heart Failure - Pipeline Products Glance 14
Late Stage Products 14
Clinical Stage Products 15
Early Stage Products 16
Chronic Heart Failure - Products under Development by Companies 17
Chronic Heart Failure - Products under Investigation by Universities/Institutes 18
Chronic Heart Failure - Companies Involved in Therapeutics Development 19
Amgen Inc. 19
AnGes MG, Inc. 20
Bayer AG 21
Capricor Therapeutics, Inc. 22
Celyad SA 23
Juventas Therapeutics, Inc. 24
Laboratoires Pierre Fabre SA 25
Les Laboratoires Servier SAS 26
Mast Therapeutics, Inc. 27
Mesoblast Limited 28
Novartis AG 29
Pfizer Inc. 30
PhaseBio Pharmaceuticals, Inc. 31
Sanofi 32
Stemedica Cell Technologies, Inc. 33
Vichem Chemie Research Ltd. 34
Zensun (Shanghai) Sci & Tech Co., Ltd. 35
Chronic Heart Failure - Therapeutics Assessment 36
Assessment by Monotherapy Products 36
Assessment by Combination Products 37
Assessment by Target 38
Assessment by Mechanism of Action 40
Assessment by Route of Administration 42
Assessment by Molecule Type 44
Drug Profiles 46
(sacubitril + valsartan) - Drug Profile 46
Product Description 46
Mechanism of Action 46
R&D Progress 46
BAY-1067197 - Drug Profile 49
Product Description 49
Mechanism of Action 49
R&D Progress 49
beperminogene perplasmid - Drug Profile 50
Product Description 50
Mechanism of Action 50
R&D Progress 50
C3BSCQR-1 - Drug Profile 55
Product Description 55
Mechanism of Action 55
R&D Progress 55
cenderitide - Drug Profile 57
Product Description 57
Mechanism of Action 57
R&D Progress 57
CLR-325 - Drug Profile 59
Product Description 59
Mechanism of Action 59
R&D Progress 59
F-373280 - Drug Profile 60
Product Description 60
Mechanism of Action 60
R&D Progress 60
finerenone - Drug Profile 61
Product Description 61
Mechanism of Action 61
R&D Progress 61
furosemide - Drug Profile 62
Product Description 62
Mechanism of Action 62
R&D Progress 62
ivabradine hydrochloride - Drug Profile 63
Product Description 63
Mechanism of Action 63
R&D Progress 63
JVS-100 - Drug Profile 64
Product Description 64
Mechanism of Action 64
R&D Progress 64
MPC-150IM - Drug Profile 66
Product Description 66
Mechanism of Action 66
R&D Progress 66
Neucardin - Drug Profile 68
Product Description 68
Mechanism of Action 68
R&D Progress 68
omecamtiv mecarbil MR - Drug Profile 70
Product Description 70
Mechanism of Action 70
R&D Progress 70
PB-1046 - Drug Profile 73
Product Description 73
Mechanism of Action 73
R&D Progress 73
rivaroxaban - Drug Profile 75
Product Description 75
Mechanism of Action 75
R&D Progress 75
SAR-296968 - Drug Profile 81
Product Description 81
Mechanism of Action 81
R&D Progress 81
serelaxin - Drug Profile 82
Product Description 82
Mechanism of Action 82
R&D Progress 82
sildenafil citrate - Drug Profile 84
Product Description 84
Mechanism of Action 84
R&D Progress 84
Small Molecules for Chronic Heart Failure - Drug Profile 86
Product Description 86
Mechanism of Action 86
R&D Progress 86
Stem Cell Therapy for Cardiovascular Disease, CNS Disorders, Metabolic Disorders, Respiratory Disease, Infectious Disease and Toxicology - Drug Profile 87
Product Description 87
Mechanism of Action 87
R&D Progress 87
Synthetic Peptide to Activate Erythropoietin Receptor for Cardiovascular Diseases - Drug Profile 90
Product Description 90
Mechanism of Action 90
R&D Progress 90
vepoloxamer - Drug Profile 91
Product Description 91
Mechanism of Action 91
R&D Progress 91
vericiguat - Drug Profile 93
Product Description 93
Mechanism of Action 93
R&D Progress 93
Chronic Heart Failure - Recent Pipeline Updates 94
Chronic Heart Failure - Dormant Projects 145
Chronic Heart Failure - Discontinued Products 147
Chronic Heart Failure - Product Development Milestones 148
Featured News & Press Releases 148
Apr 04, 2016: Cytokinetics Announces Start of Phase 2 Clinical Trial of Omecamtiv Mecarbil in Japanese Subjects With Heart Failure 148
Apr 04, 2016: Results Of Vepoloxamer Nonclinical Studies In Advanced Heart Failure Presented At American College Of Cardiology 65th Annual Scientific Sessions & Expo 148
Apr 02, 2016: New analyses show Novartis' Entresto reduced cardiovascular death or hospitalization for heart failure, consistently benefitting patients with reduced ejection fraction regardless 149
Mar 22, 2016: CardioCell Expands Chronic Heart Failure Phase IIa Clinical Trial to MedStar Washington Hospital Center 150
Mar 18, 2016: Celyad notifies the European Medicines Agency of its intention to file a Marketing Authorization Application for C-Cure 151
Jan 20, 2016: Breakthrough drug for heart failure now available in the UK 151
Dec 23, 2015: Celyad to Address US Institutional Investors in January at J.P. Morgan Healthcare Conference 152
Dec 21, 2015: Celyad receives clearance from the US FDA on its CHART-2 Phase III IND 153
Dec 02, 2015: New heart failure therapy projected to increase life expectancy 153
Dec 01, 2015: CardioCell Plans Phase IIb Clinical Trial Using Its Stem Cells for Patients With Chronic Heart Failure 154
Appendix 156
Methodology 156
Coverage 156
Secondary Research 156
Primary Research 156
Expert Panel Validation 156
Contact Us 156
Disclaimer 157

List of Tables

Number of Products under Development for Chronic Heart Failure, H1 2016 10
Number of Products under Development for Chronic Heart Failure - Comparative Analysis, H1 2016 11
Number of Products under Development by Companies, H1 2016 12
Number of Products under Investigation by Universities/Institutes, H1 2016 13
Comparative Analysis by Late Stage Development, H1 2016 14
Comparative Analysis by Clinical Stage Development, H1 2016 15
Comparative Analysis by Early Stage Development, H1 2016 16
Products under Development by Companies, H1 2016 17
Products under Investigation by Universities/Institutes, H1 2016 18
Chronic Heart Failure - Pipeline by Amgen Inc., H1 2016 19
Chronic Heart Failure - Pipeline by AnGes MG, Inc., H1 2016 20
Chronic Heart Failure - Pipeline by Bayer AG, H1 2016 21
Chronic Heart Failure - Pipeline by Capricor Therapeutics, Inc., H1 2016 22
Chronic Heart Failure - Pipeline by Celyad SA, H1 2016 23
Chronic Heart Failure - Pipeline by Juventas Therapeutics, Inc., H1 2016 24
Chronic Heart Failure - Pipeline by Laboratoires Pierre Fabre SA, H1 2016 25
Chronic Heart Failure - Pipeline by Les Laboratoires Servier SAS, H1 2016 26
Chronic Heart Failure - Pipeline by Mast Therapeutics, Inc., H1 2016 27
Chronic Heart Failure - Pipeline by Mesoblast Limited, H1 2016 28
Chronic Heart Failure - Pipeline by Novartis AG, H1 2016 29
Chronic Heart Failure - Pipeline by Pfizer Inc., H1 2016 30
Chronic Heart Failure - Pipeline by PhaseBio Pharmaceuticals, Inc., H1 2016 31
Chronic Heart Failure - Pipeline by Sanofi, H1 2016 32
Chronic Heart Failure - Pipeline by Stemedica Cell Technologies, Inc., H1 2016 33
Chronic Heart Failure - Pipeline by Vichem Chemie Research Ltd., H1 2016 34
Chronic Heart Failure - Pipeline by Zensun (Shanghai) Sci & Tech Co., Ltd., H1 2016 35
Assessment by Monotherapy Products, H1 2016 36
Assessment by Combination Products, H1 2016 37
Number of Products by Stage and Target, H1 2016 39
Number of Products by Stage and Mechanism of Action, H1 2016 41
Number of Products by Stage and Route of Administration, H1 2016 43
Number of Products by Stage and Molecule Type, H1 2016 45
Chronic Heart Failure Therapeutics - Recent Pipeline Updates, H1 2016 94
Chronic Heart Failure - Dormant Projects, H1 2016 145
Chronic Heart Failure - Dormant Projects (Contd..1), H1 2016 146
Chronic Heart Failure - Discontinued Products, H1 2016 147